Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Langerhans cell histiocytosis]

F Hefti1, G Jundt

  • 1Kinderorthopädische Universitätsklinik, Basel.

Der Orthopade
|February 1, 1995
PubMed
Summary
This summary is machine-generated.

Langerhans cell histiocytosis (LCH) is a rare immune system disorder. Treatment for bone lesions is surgical, while soft-tissue involvement may require chemotherapy, cortisone, or interferon therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

We thrive not when we've done it all, but when we still have more to do (S. Lewis).

Journal of children's orthopaedics·2022
Same author

Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2019
Same author

Culture of Bone Biopsy Specimens Overestimates Rate of Residual Osteomyelitis After Toe or Forefoot Amputation.

The Journal of bone and joint surgery. American volume·2018
Same author

[Cartilage, bones, chorda : Molecular pathology].

Der Pathologe·2018
Same author

<i>LABOR OMNIA VINCIT IMPROBUS</i> - Labour conquers all things: An Impact Factor for JCO!

Journal of children's orthopaedics·2018
Same author

Impact of Single Center Treatment on Ewing Sarcoma 10-Year Long Term Survival Rates.

Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca·2018

Area of Science:

  • Pathology
  • Immunology
  • Oncology

Context:

  • Langerhans cell histiocytosis (LCH) is a non-neoplastic granuloma-like lesion of unknown origin.
  • Formerly known as "eosinophilic granuloma" or "histiocytosis X," LCH is characterized by the proliferation of specific cells and inflammatory infiltrates.
  • LCH can manifest as solitary or multifocal lesions, with or without soft-tissue involvement, and includes specific entities like Hand-Schüller-Christian disease and Letterer-Siwe disease.

Purpose:

  • To describe the clinical and pathological features of Langerhans cell histiocytosis (LCH).
  • To analyze the epidemiological data and treatment outcomes for LCH based on cases from the Swiss bone tumor reference center.
  • To provide treatment recommendations for osseous and soft-tissue involvement in LCH.

Summary:

Related Experiment Videos

  • The study reviewed 130 LCH cases, noting frequent involvement of the mandible, skull, ribs, and femur.
  • Most lesions occurred in the first three decades of life, with a male predominance.
  • Treatment strategies varied based on disease manifestation: surgery for osseous lesions and chemotherapy, cortisone, or interferon for soft-tissue involvement.

Impact:

  • This research clarifies the diverse presentations and treatment approaches for Langerhans cell histiocytosis.
  • Findings support a tailored treatment strategy, emphasizing surgery for bone lesions and alternative therapies for soft-tissue disease.
  • The study contributes to understanding LCH epidemiology and optimizing patient management.